Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 10 | 13 | +2,46 % | ||
| IMMUNITYBIO | 9 | 3 | +37,52 % | ||
| BRIDGEBIO PHARMA | 6 | - | +1,06 % | ||
| MODERNA | 4 | 16 | +5,66 % | ||
| ALNYLAM PHARMACEUTICALS | 3 | 9 | -0,06 % | ||
| ARBUTUS BIOPHARMA | 3 | - | -14,09 % | ||
| EXELIXIS | 2 | 8 | -2,07 % | ||
| ANI PHARMACEUTICALS | 2 | 5 | -2,03 % | ||
| APELLIS PHARMACEUTICALS | 2 | 4 | -2,50 % | ||
| AXSOME THERAPEUTICS | 2 | 1 | -0,33 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20:31 | Why ImmunityBio Stock Is Skyrocketing Again Today | 6 | The Motley Fool | ||
| 20:30 | EILMELDUNG: Biontech startet durch - beginnt jetzt die Rallye? - das müssen Sie jetzt wissen! | Hebelschein-Spekulant | |||
| 20:12 | Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma | 6 | Seeking Alpha | ||
| 19:54 | Genmab reports positive phase 3 trial results for epcoritamab | 3 | Investing.com | ||
| 19:46 | Genmab: Epcoritamab zeigt in Phase-3-Studie verbessertes progressionsfreies Überleben | 7 | Investing.com Deutsch | ||
| 19:42 | GENMAB A/S - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 19:42 | Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action | 1 | Benzinga.com | ||
| 19:36 | Genmab A/S: Genmab Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | 220 | Business Wire | Company Announcement Based on the topline results from the EPCORE DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps Genmab A/S (Nasdaq: GMAB) today announced... ► Artikel lesen | |
| 19:26 | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | 198 | Newsfile | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| 19:26 | I Hope Moderna (MRNA) Posts Growth, Says Jim Cramer | 13 | Insider Monkey | ||
| 19:10 | Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO | 6 | FiercePharma | ||
| 18:54 | ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline | 13 | Benzinga.com | ||
| 17:50 | IMMUNITYBIO INC zeigt anhaltende innere Stärke | 18 | Maximilian Berger | ||
| 17:26 | Rigel Pharmaceuticals, Inc. (RIGL) Releases Preliminary Results for Q4 2025 | 1 | Insider Monkey | ||
| 17:06 | ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I-Told-You-So | 12 | Benzinga.com | ||
| 16:34 | Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia | 2 | Zacks | ||
| 16:34 | Mirum Stock Rises 7% in a Week: Here's What You Should Know | 1 | Zacks | ||
| 16:19 | ImmunityBio touts 15-month complete response in off-the-shelf CAR-NK trial | 14 | FierceBiotech | ||
| 15:45 | Bayer: Kein Vergleich mit AstraZeneca | 497 | 4investors | Im Rahmen einer Branchenstudie blicken die Analysten der UBS auch auf die Aktien von Bayer. Dabei geht es nicht nur um die Perspektiven im neuen Jahr. Der Blick richtet sich auf die kommenden fünf Jahre.... ► Artikel lesen | |
| 15:31 | Piper Sandler raises Axsome Therapeutics price target to $223 on growth outlook | 8 | Investing.com |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .